Pfizer Doubles Down on MRNA Tech With Three Deals

Pfizer Inc has signed three deals to broaden the use of the messenger RNA technology (mRNA) that its COVID-19 vaccine was based on, including a pact worth as much as $1.35 billion with gene-editing specialist Beam Therapeutics.

Pfizer will also collaborate with Codex DNA Inc for an undisclosed sum to leverage the biotech’s proprietary technology, which could enable more efficient development of mRNA-based vaccines, therapeutics and other biopharma products. Its collaboration with private biotech Acuitas Therapeutics will focus on the use of the Vancouver-based company’s lipid nanoparticle (LNP) technology for developing up to ten vaccines or therapeutics. The financial details of the deal were not disclosed

We are primarily funded by readers. Please subscribe and donate to support us!

Looks like they’re planning on changing mankind (or what’s left of it) for the foreseeable future



Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.